Analyst Upgrades: J.C. Penney Company, Inc., First Solar, Inc., and ACADIA Pharmaceuticals Inc.

Analysts upwardly revised their ratings on J C Penney Company Inc (JCP), First Solar, Inc. (FSLR), and ACADIA Pharmaceuticals Inc. (ACAD)

by Alex Eppstein

Published on Feb 24, 2015 at 9:20 AM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are weighing in today on department store chain J C Penney Company Inc (NYSE:JCP), alternative energy issue First Solar, Inc. (NASDAQ:FSLR), and drugmaker ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Here's a quick roundup of today's bullish brokerage notes on JCP, FSLR, and ACAD.

  • JCP is pointed 1.5% higher ahead of the open, after Piper Jaffray underscored the stock's status as a "Top Pick for 2015," along with an "overweight" rating and $12 price target. The bullish note comes as little surprise, considering J C Penney Company Inc has advanced 30.7% year-to-date to trade at $8.47. Options traders are in the bulls' corner, as well. The stock's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 4.65 ranks just 4 percentage points from a 12-month high. Looking ahead, JCP will report fourth-quarter earnings Thursday evening, and the Street is looking for a per-share profit of 11 cents.

  • FSLR, which will step into the confessional tonight, is up 15% ahead of the bell. Powering the move higher is news of a potential joint venture with sector peer SunPower Corporation (NASDAQ:SPWR), as well as a subsequent upgrade to "buy" from "hold" at Deutsche Bank -- which also raised its price target to $68 from $60. On the charts, First Solar, Inc. has had a solid start to 2015, tacking on more than 11% to trade at $49.64. Option bulls have responded, too, as the equity's 10-day ISE/CBOE/PHLX call/put volume ratio of 3.31 sits in the 81st percentile of its annual range.

  • Finally, ACAD has surged 18.5% year-to-date to perch at $37.62, and is pointed 1.7% higher -- and headed for record-high territory -- in pre-market trading, after H.C. Wainwright initiated coverage with a "buy" rating and $50 price target. This bullish brokerage attention is just more of the same for ACADIA Pharmaceuticals Inc., which has received seven "strong buy" recommendations, compared to one "hold" and not a single "sell." Meanwhile, the company will divulge fourth-quarter numbers after the close this Thursday, with at least one group of option players gambling on post-event upside.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Nevada Discovery That Could Jeopardize Chinese Dominance
Click to continue to advertiser's site.
UNH Stock Pops on Accelerated Payment Promise
Analysts are very bullish on UnitedHealth stock
Extra Space Storage Stock Wavers After Downgrade
Raymond James downgraded to "underperform" from "market perform"
The Top Lithium Play of 2020
Click to continue to advertiser's site.